12:00 AM
May 18, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AG013: Phase Ib start

Next month, ActoGeniX will begin a single-blind, placebo-controlled, dose-escalation, U.S. Phase Ib trial to evaluate AG013 given one, three or six...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >